The Procter & Gamble Company announced that it is collaborating with Cleveland Clinic and Cleveland HeartLab to develop and commercialize a diagnostic and management solution for a recently-discovered heart disease biomarker. As part of the partnership, Cleveland HeartLab will develop a diagnostic test to measure blood levels of TMAO, while Cleveland Clinic will work with Procter & Gamble to develop an over-the-counter product that could help people manage their TMAO levels.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
165.2 USD | +0.84% |
|
+0.18% | +12.74% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.74% | 390B | |
+13.92% | 138B | |
+21.75% | 79.62B | |
-4.36% | 71.68B | |
-27.28% | 38.13B | |
-14.96% | 35.06B | |
+0.41% | 33.01B | |
+9.36% | 18.3B | |
+21.45% | 16.83B | |
+8.84% | 12.87B |
- Stock Market
- Equities
- PG Stock
- News Procter & Gamble Company
- Procter & Gamble Partners with Cleveland Clinic & Cleveland HeartLab to Develop Heart Disease Biomarker